Amoneta Diagnostics SAS
Channel: Firalis Group
Date: 22/06/2018

Amoneta Diagnostic is finalizing a multicentral clinical study to qualify its innovative biomarkers, and thanks a very well protected IP portfolio, will finally put in the market a simple, non-invasive and reliable blood test for the early Diagnosis of Alzheimer's Disease.